
Ipsen Kartos Therapeutics Acquisition Worth 1.75B Expands Oncology Pipeline with Myelofibrosis Drug
Ipsen, the biopharmaceutical company, recently announced a definitive merger agreement to acquire Kartos Therapeutics. Under this Ipsen Kartos Therapeutics Acquisition,